Rashwan Ghada, Jumani Adil, Ibrahim Hadiza, AlNajjar Majdi
Internal Medicine, Zayed Military Hospital, Abu Dhabi, ARE.
Endocrinology, Zayed Military Hospital, Abu Dhabi, ARE.
Cureus. 2025 Apr 28;17(4):e83123. doi: 10.7759/cureus.83123. eCollection 2025 Apr.
Levothyroxine malabsorption is a rare but important cause of refractory hypothyroidism that necessitates alternative therapeutic approaches. We present the case of a 55-year-old woman with long-standing hypothyroidism who continued to experience persistent symptoms despite being on high-dose oral levothyroxine (1500 mcg daily). Laboratory investigations revealed an elevated thyroid-stimulating hormone (TSH) level of 14.160 mIU/L, along with positive anti-gliadin and anti-parietal cell antibodies. A supervised thyroxine (T4) absorption test confirmed true levothyroxine malabsorption. The patient was subsequently transitioned to a liquid levothyroxine formulation at a reduced dose of 600 mcg, which led to significant clinical improvement and normalization of thyroid function. Levothyroxine malabsorption can be attributed to underlying gastrointestinal conditions such as celiac disease and atrophic gastritis. The T4 malabsorption test is a valuable tool in distinguishing true malabsorption from non-adherence or pseudo-malabsorption. In cases of confirmed malabsorption, liquid or parenteral formulations may help improve absorption and lead to better clinical outcomes. This case highlights the importance of identifying thyroid hormone malabsorption in patients with refractory hypothyroidism to ensure optimal management and therapeutic success.
左甲状腺素吸收不良是难治性甲状腺功能减退症的一种罕见但重要的病因,需要采取替代治疗方法。我们报告一例55岁患有长期甲状腺功能减退症的女性病例,尽管服用高剂量口服左甲状腺素(每日1500微克),她仍持续出现症状。实验室检查显示促甲状腺激素(TSH)水平升高至14.160 mIU/L,同时抗麦胶蛋白抗体和抗壁细胞抗体呈阳性。一项有监督的甲状腺素(T4)吸收试验证实存在真正的左甲状腺素吸收不良。该患者随后改用剂量减至600微克的液体左甲状腺素制剂,这导致了显著的临床改善和甲状腺功能正常化。左甲状腺素吸收不良可归因于潜在的胃肠道疾病,如乳糜泻和萎缩性胃炎。T4吸收试验是区分真正的吸收不良与不依从或假性吸收不良的一项有价值的工具。在确诊吸收不良的病例中,液体或肠外制剂可能有助于改善吸收并带来更好的临床结果。该病例强调了在难治性甲状腺功能减退症患者中识别甲状腺激素吸收不良对于确保最佳管理和治疗成功的重要性。